T
Travere Therapeutics
Biotech & Life Sciences · San Diego, United States · Founded 2011 · IPO 2012
Developing and delivering therapies for rare kidney and metabolic diseases MoreLess
Travere Therapeutics is a biopharmaceutical company that identifies, develops, and delivers therapies for people living with rare diseases. The company was founded in 2011 and is based in San Diego, California.
Travere Therapeutics has a portfolio of commercial-stage therapies and a pipeline of product candidates for a range of rare diseases, with a focus on rare kidney and metabolic disorders. The company's commercial products include Thiola and Thiola EC for cystinuria, and Chenodal for gallstones. Its pipeline includes sparsentan for focal segmental glomerulosclerosis and IgA nephropathy.
The company's business model is focused on the development and commercialization of therapies for rare diseases. Travere Therapeutics generates revenue from the sale of its commercial products. The company also has a patient support program that provides resources and assistance to patients and their families.
Keywords: biopharmaceutical, rare diseases, kidney disorders, metabolic disorders, drug development, commercialization, patient support, Thiola, Chenodal, sparsentan
Company overview
Travere Therapeutics company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2011
- Headquarters
- San Diego, United States
- Employees
- 520
- Open positions
- 55
- Dealroom signal
- 90.6
- Investment activity
- 3 companies · latest Oct 2020
- Capital deployed
- $2.5M
- Preferred round
- ACQUISITION
Valuation & funding
Travere Therapeutics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO CONVERTIBLE✓Other financing | May 2026 | $475M | — | Undisclosed | ↗ |
| POST IPO EQUITY✓Other financing | Jan 2026 | $0 | — | Palisades Investment Partners | ↗ |
| Other✓Other financing | Nov 2024 | $125M | — | Undisclosed | ↗ |
| POST IPO EQUITY✓Other financing | Mar 2023 | $200M | — | Undisclosed | ↗ |
| POST IPO DEBT✓Debt | Mar 2022 | $275M | — | Undisclosed | ↗ |
| POST IPO EQUITY✓Other financing | Feb 2021 | Undisclosed | — | ||
| POST IPO EQUITY✓Other financing | Mar 2015 | Undisclosed | ↗ | ||
| POST IPO EQUITY✓Other financing | May 2014 | Athyrium Capital Management | — | ||
| POST IPO EQUITY✓Other financing | Aug 2013 | Undisclosed | — | ||
| IPO✓Exit | Dec 2012 | Undisclosed | ↗ |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
Growth signals
Travere Therapeutics website traffic
Latest recorded traffic for Travere Therapeutics is 24K monthly website visits, down 31.4% over the last three months. Travere Therapeutics's team grew 27.1% over the past year.
Hiring
Open positions at Travere Therapeutics
Current openings linked to this company in Dealroom.
Comparisons
Travere Therapeutics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Capital deployed
Travere Therapeutics investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Orphan TechnologiesLondon, United Kingdom
$90Mvaluation
PerlaraSan Francisco, United StatesPerlara, PBC is precision drug discovery that leaves no mutation behind
$17Mvaluation
MP
Manchester PharmaceuticalsFort Collins, United StatesManchester Pharmaceuticals has been acquired by Retrophin
→
Talent graph
Travere Therapeutics's talent
Source: Dealroom Talent Intelligence.
Investors
4 investors on Travere Therapeutics's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Travere Therapeutics has talent and traffic
team presence
In the news
Latest news about Travere Therapeutics
Recent press, funding announcements, and product moves mentioning Travere Therapeutics — open to read from the original sources.
Market sentiment
What the market is saying about Travere Therapeutics
An AI-synthesized read of the highest-engagement posts about Travere Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Travere Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.